Page 230 - 2021_10-Haematologica-web

Letters to the Editor
Janssen, Celgene, Novartis, Amgen, and Takeda; consulting or adviso- ry role for BMS, Janssen, Celgene, Novartis, Amgen, and Takeda; speakers bureau for Takeda; research funding from Takeda, and Novartis; and travel, accommodation, and expenses from BMS, Janssen, Celgene, Novartis, Amgen, and Takeda. HG reports hono- raria from Amgen, BMS, Celgene, Chugai, Janssen, Novartis, and Takeda; consulting or advisory role for Amgen, BMS, Celgene, Chugai, Janssen, Novartis, and Takeda; speakers’ bureau for Amgen, BMS, Celgene, Janssen, Novartis, and Takeda; research funding from Amgen, BMS, Celgene, Chugai, Janssen, Novartis, and Takeda; and travel, accommodation and expenses from BMS, Celgene, Janssen, Novartis, and Takeda. GHJ has received consultancy fees, honoraria and speakers’ bureau fees from Roche, Amgen, Janssen, and Merck Sharp and Dohme; and consultancy fees, honoraria, travel support, research funding, and speakers’ bureau fees from Celgene Corporation and Takeda. MFK has received consultancy fees and travel support from Janssen, BMS and Takeda; consultancy fees from AbbVie, Seattle Genetics, and GSK; consultancy fees and honoraria from Amgen; and consultancy fees and research funding from Karyopharm, Janssen and Celgene Corporation. All other authors report no conflicts of interest.
Contributions: NW and MFK designed the study and analyzed the data; NW, RSH and MFK wrote the manuscript; NW, MFK, HJS, DAC, MSR, GW, IWB, UB, TH, GJM, AJ, FED, MH, GC, CS, HG and GJ collected and curated data, revised and approved the manuscript.
Acknowledgments: the authors are grateful for the support of the Clinical Trials Research Unit (CTRU) at Leeds and the NCRI Haematological Oncology Clinical Studies Group. The GMMG thanks the Koordinierungszentrum für Klinische Studien (KKS) Heidelberg for support of the trial and data monitoring and all participating investigators, centers, patients and their families.
Funding: NCRI Myeloma XI-related work was supported by research grants from Myeloma UK and infrastructure support from
the National Institute of Health Biomedical Research Centre at the Royal Marsden Hospital and Institute of Cancer Research, London. Martin Kaiser was supported by a Jacquelin Forbes-Nixon Fellowship. Primary financial support for NCRI Myeloma XI was provided by Cancer Research UK (C1298/A10410). The GMMG MM5 trial was supported by Celgene, Chugai, Janssen-Cilag and The Binding Site. The GMMG HD4 trial corresponds to the German part of the joint HOVON-65/GMMG-HD4 trial, which was supported by
the Dutch Cancer Foundation, by the German Federal Ministry of Education and Research, and by a grant from Janssen Cilag.
The GMMG also received grants for this trial from Novartis, Amgen, Chugai, Roche, and the Tumorzentrum Heidelberg/Mannheim.
References
1. Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implica- tions. Nat Rev Clin Oncol. 2017;14(2):100-113.
2. Shah V, Sherborne AL, Walker BA, et al. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular pro- files of 1905 trial patients. Leukemia. 2018;32(1):102-110.
3. Croft J, Ellis S, Sherborne AL, et al. Copy number evolution and its relationship with patient outcome-an analysis of 178 matched pres- entation-relapse tumor pairs from the Myeloma XI trial. Leukemia. 2021;35(7):2043-2053.
4. Schmidt TM, Barwick BG, Joseph N, et al. Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer J. 2019;9(12):94.
5. Abdallah N, Greipp P, Kapoor P, et al. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv. 2020;4(15):3509-3519.
6. Walker BA, Mavrommatis K, Wardell CP, et al. A high-risk, double- hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33(1):159-170.
7. Perrot A, Lauwers-Cances V, Tournay E, et al. Development and val- idation of a cytogenetic prognostic index predicting survival in mul- tiple myeloma. J Clin Oncol. 2019;37(19):1657-1665.
8. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-2869.
9. Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(1):57-73.
10. Goldschmidt H, Lokhorst HM, Mai EK, et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia. 2018; 32(2):383-390.
11. Goldschmidt H, Mai EK, Dürig J, et al. Response-adapted lenalido- mide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia. 2020;34(7):1853-1865.
12. Neben K, Lokhorst HM, Jauch A, et al. Administration of borte- zomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119(4):940-948.
13. Rajkumar SV, Harousseau J-L, Durie B, et al. Consensus recommen- dations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011; 117(18):4691-4695.
14. Weinhold N, Ashby C, Rasche L, et al. Clonal selection and double- hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016;128(13):1735-1744.
15.Mayo Clinic. Mayo Clinic mSMART: Risk adapted approach to management of multiple myeloma and related disorders. mSMART 3.0. https://www.msmart.org/s/Treatment-of-Newly-Diagnosed- Myelomav18_June-20FINAL.pdf (accessed January 18, 2021).
2758
haematologica | 2021; 106(10)